According to the company, Servier has previously successfully identified and validated therapeutic compounds from Tripos’ LeadQuest compound collection. As a result of this, Servier has now chosen to partner with Tripos to further design and synthesize compounds for potential drug development.
Tripos will employ its ChemSpace and LeadHopping technologies and integrated knowledge-driven chemistry processes to identify additional novel chemistries against the same targets. Tripos’ ChemSpace technology is used to quickly identify similar but distinct chemical entities, while its LeadHopping technology helps scientists navigate the patent space.
“By applying our proprietary chemistry processes, Servier will be able to identify potential leads much sooner, therefore accelerating the research process,” commented Dr Mark Allen, senior vice president and managing director of Tripos Discovery Research. “We hope the success we generate through this drug discovery project will lay the foundation for future Tripos and Servier partnerships and developments.”